View article

Equine adipose-derived mesenchymal stem cells (Eq adMSC) are a potential cell source for cell therapy due to their capacity to self-renew and differentiate in specialised cell types. In 2006, the International Society for Cellular Therapy (ISCT) defined human MSC as aplastic-adherent cells showing the capacity of tri-lineage differentiation that express specific surface markers (i.e. CD73, CD90, and CD105). In 2013, under the statements of the ISCT and International Federation of Adipose Therapeutics (IFAT), Bourin et al. added CD44 and CD29 to the list of MSC-specific surface antigens and recommended to include in the validation some markers of functionality and viability. Establishing a specific Eq adMSC panel has, up to now, never been done and is complicated by the nonavailability of equine-specific antibodies. Indeed, to our knowledge, only CD44 and MHCII equine-specific monoclonal antibodies are …